Holen Sie sich die Stockscreener-App
17.18
3.61%
-0.6427
Schlusskurs vom Vortag:
$17.82
Offen:
$17.58
24-Stunden-Volumen:
857.27K
Relative Volume:
0.69
Marktkapitalisierung:
$1.42B
Einnahmen:
$46.02M
Nettoeinkommen (Verlust:
$-70.80M
KGV:
-9.4381
EPS:
-1.82
Netto-Cashflow:
$-1.61M
1W Leistung:
+25.47%
1M Leistung:
+53.23%
6M Leistung:
+92.35%
1J Leistung:
+94.09%
1-Tages-Spanne:
$17.16
$18.17
1-Wochen-Bereich:
$13.78
$19.11
52-Wochen-Spanne:
$3.91
$19.11
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Pharmaceuticals Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Vergleichen Sie EYPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
17.17 | 1.48B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Pharmaceuticals Inc Aktie (EYPT) Neueste Nachrichten
EyePoint stock maintains Outperform rating at Mizuho amid competitor moves By Investing.com - Investing.com India
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Walleye Capital LLC Has $1.88 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint (EYPT) Is Up 25.0% After DURAVYU Phase 3 Safety Green Light And $200M ATM Offering - simplywall.st
Federated Hermes Inc. Has $43.28 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Understanding Momentum Shifts in (EYPT) - news.stocktradersdaily.com
EyePoint Pharmaceuticals changes name to EyePoint Inc - marketscreener.com
EyePoint Pharmaceuticals changes name to EyePoint, Inc., retains EYPT ticker - Investing.com
EyePoint Pharmaceuticals Announces Official Name Change - TipRanks
EyePoint Pharmaceuticals changes name to EyePoint, Inc., retains EYPT ticker By Investing.com - Investing.com India
EyePoint Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Sets New 12-Month HighHere's What Happened - MarketBeat
How EyePoint Pharmaceuticals Inc. (PV3B) stock responds to job market shiftsMarket Growth Review & Community Consensus Trade Signals - Newser
Can EyePoint Pharmaceuticals Inc. (PV3B) stock deliver strong annual returnsWeekly Trading Summary & Real-Time Volume Trigger Notifications - Newser
How buyback programs support EyePoint Pharmaceuticals Inc. (PV3B) stockMarket Risk Report & Smart Investment Allocation Tips - Newser
Will EyePoint Pharmaceuticals Inc. stock outperform value stocksQuarterly Portfolio Review & AI Powered Trade Plan Recommendations - Newser
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD - Investing.com
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD By Investing.com - Investing.com South Africa
Will EyePoint Pharmaceuticals Inc. (PV3B) stock outperform energy sector in 2025CPI Data & Weekly Return Optimization Plans - Newser
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Is EyePoint Pharmaceuticals Inc. (PV3B) stock positioned for secular growthWeekly Earnings Recap & Fast Entry Momentum Alerts - Newser
EyePoint Pharmaceuticals: Promising Outlook for Duravyu in Wet AMD Treatment and Strategic Growth Potential - TipRanks
EyePoint Pharmaceuticals Director Sells Shares - TradingView
XTX Topco Ltd Acquires 94,210 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
What drives EyePoint Pharmaceuticals Inc stock priceEvening Star Patterns & Exceptional Return Capital - earlytimes.in
Investors Appear Satisfied With EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Prospects As Shares Rocket 26% - 富途牛牛
EyePoint Pharmaceuticals (EYPT) Is Up 8.4% After Positive Phase 3 Safety Review for DURAVYU - Sahm
Officer/Dir Lurker Files To Sell 500 Of EyePoint Pharmaceuticals Inc [EYPT] - TradingView
What analysts say about EyePoint Pharmaceuticals Inc PV3B stockHigh Dividend Yield Stocks & Access Free Risk Analysis Before You Invest - earlytimes.in
Avoiding Lag: Real-Time Signals in (EYPT) Movement - news.stocktradersdaily.com
EyePoint Pharmaceuticals (EYPT): A Fresh Valuation Look Following Key DURAVYU Phase 3 Safety Review Completion - Sahm
Will EyePoint Pharmaceuticals Inc. stock see PE expansionJuly 2025 Patterns & Stepwise Entry and Exit Trade Signals - BỘ NỘI VỤ
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Raised to "Strong-Buy" at Cantor Fitzgerald - MarketBeat
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 By Investing.com - Investing.com Nigeria
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 - Investing.com
EyePoint receives second consecutive positive recommendation from DSMC - Modern Retina
Why Institutions Believe Infibeam Avenues Limited Is Undervalued TodayStock Watchlist Updates & Collaborate and Win Together - earlytimes.in
EyePoint Pharmaceuticals (EYPT) Clears Phase 3 Safety Hurdle for DURAVYU—Is a New Wet AMD Era Ahead? - Sahm
Can EyePoint Pharmaceuticals Inc. (PV3B) stock sustain double digit ROETrade Risk Report & Detailed Earnings Play Alerts - newser.com
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock beat growth indexesExit Point & Daily Technical Forecast Reports - newser.com
Is EyePoint Pharmaceuticals Inc. (PV3B) stock trading at attractive multiplesEarnings Risk Summary & Smart Swing Trading Alerts - newser.com
Is EyePoint Pharmaceuticals Inc. stock attractive for passive investorsJuly 2025 Summary & Scalable Portfolio Growth Methods - newser.com
Why ETFs are accumulating EyePoint Pharmaceuticals Inc. (PV3B) stock2025 Biggest Moves & Free Reliable Trade Execution Plans - newser.com
What margin trends mean for EyePoint Pharmaceuticals Inc. stockForecast Cut & Daily Technical Forecast Reports - newser.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock hit Wall Street targetsQuarterly Earnings Summary & Daily Oversold Bounce Ideas - newser.com
Finanzdaten der Eyepoint Pharmaceuticals Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):